Lipomics Technologies, which specialises in clinical diagnostic development, is engaged in a research collaboration with Joslin Diabetes Center's insulin resistance research
The collaboration between Lipomics and Joslin will initially focus on two research programmes.
The first is a study on insulin resistant patients with a family history of Type 2 diabetes.
The primary objective is to identify predictive markers of disease that can be translated into blood based diagnostics.
The second study will focus on understanding the effects of gastric bypass surgery on insulin sensitivity.
Both research programs originate from the laboratories of Mary Elizabeth Patti and Allison Goldfine, both assistant professors of medicine at Harvard Medical School and investigators at Joslin Diabetes Center.
"We are excited about this collaboration and anticipate that the unique technology at Lipomics will generate interesting results and advance our research programs, as we believe that lipid metabolism is a critical component of diabetes risk," said Patti.
Lipomics is developing diagnostic monitoring tools for the management of Type 2 diabetes.
"It is an honour to work with Dr Patti and a premier research institution like the Joslin Diabetes Center.
"We believe that this collaboration will provide access to valuable clinical samples in support of our diagnostic development programs," said Steve Watkins, chief executive officer at Lipomics.
Lipomics will retain certain rights to develop diagnostic applications based on data emerging from these studies.
